
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways (with roles)<br>---------------------------------------------------<br><br>I‚Äôll first group the most informative genes by function, focusing on pathways that are distinctive in brain single-cell data.<br><br>**A. Wnt signaling / extracellular matrix (ECM) / fibroblast-like programs**<br><br>- **SFRP2** ‚Äì Secreted frizzled-related protein; Wnt pathway antagonist/modulator, strongly associated with fibroblast-like, perivascular, and mesenchymal cells; also seen in certain specialized glia-like stromal cells.<br>- **FRZB (SFRP3)** ‚Äì Another secreted Wnt antagonist; classic marker of mesenchymal/fibroblast-like cells and chondrocytes; in brain, often perivascular fibroblast-like cells.<br>- **NKD1** ‚Äì Negative regulator of Wnt signaling; often up in Wnt-modulated stromal/mesenchymal populations.<br>- **CTGF** ‚Äì Connective tissue growth factor; TGFŒ≤/Wnt-responsive matricellular protein; hallmark of fibroblasts, pericytes, and reactive stromal cells.<br>- **EGFL6** ‚Äì EGF-like domain-containing ECM protein; enriched in endothelial/perivascular niches and fibroblast-like cells.<br>- **SMOC2** ‚Äì SPARC-related ECM glycoprotein; strong in fibroblasts, perivascular stromal cells, and some OPC-like populations.<br>- **THSD4** ‚Äì Thrombospondin type 1 domain-containing ECM protein; associated with ECM remodeling, fibroblast-like cells.<br>- **NPNT** ‚Äì Nephronectin, ECM protein; integrin ligand; often in mesenchymal/fibroblast-like and perivascular cells.<br>- **ELN** ‚Äì Elastin; classic ECM component of vascular and fibroblast-like cells.<br>- **DCN** ‚Äì Decorin, small leucine-rich proteoglycan; canonical fibroblast/mesenchymal ECM marker.<br>- **OGN** ‚Äì Osteoglycin; another small leucine-rich proteoglycan; fibroblast/mesenchymal ECM.<br>- **CEMIP (KIAA1199)** ‚Äì Hyaluronan-binding protein involved in ECM remodeling; fibroblast-like, invasive stromal phenotypes.<br>- **FBLN1** ‚Äì Fibulin-1, ECM glycoprotein; vascular/fibroblast ECM.<br>- **ENPP6** ‚Äì Ectonucleotide pyrophosphatase; in brain, enriched in oligodendrocyte lineage and some perivascular/ECM-remodeling cells.<br>- **NOV (CCN3)** ‚Äì Matricellular protein in CCN family; expressed in vascular/perivascular and some glial progenitors.<br><br>Collectively, this is a **strong ECM/Wnt-modulated fibroblast-like/perivascular stromal signature**, not a canonical neuronal or classic astrocyte profile.<br><br>**B. Lipid metabolism / apolipoproteins / secretory**<br><br>- **APOE** ‚Äì Major apolipoprotein in CNS; high in astrocytes, microglia, and some perivascular fibroblast-like cells; involved in lipid transport and injury response.<br>- **CLU** ‚Äì Clusterin (ApoJ); secreted chaperone, complement regulator; enriched in astrocytes, choroid plexus, and some vascular-associated stromal cells.<br>- **IGFBP2, IGFBP5** ‚Äì Insulin-like growth factor binding proteins; secreted factors modulating IGF signaling; often in astrocytes, OPCs, and stromal cells.<br>- **RARRES2 (Chemerin)** ‚Äì Adipokine/chemokine; secreted; associated with stromal, adipose, and immune-interacting cells.<br>- **ADIRF** ‚Äì Adipogenesis regulatory factor; adipocyte/stromal-like gene, often in perivascular fibroblast-like cells.<br>- **CPE** ‚Äì Carboxypeptidase E; neuroendocrine/secretory granule protein, but also in some glial and stromal cells with secretory activity.<br>- **FGL2** ‚Äì Fibrinogen-like protein 2; secreted immune-modulatory protein; often in perivascular/immune-interacting stromal cells.<br><br>This points to a **secretory, paracrine, niche-supporting cell type**, not a pure neuronal population.<br><br>**C. Transporters / channels / receptors**<br><br>- **LEPR** ‚Äì Leptin receptor; in brain, enriched in hypothalamic neurons but also in some perivascular and stromal cells; here, co-occurs with strong ECM/fibroblast markers, suggesting a **perivascular leptin-responsive stromal cell** rather than neurons.<br>- **KCNMA1** ‚Äì BK large-conductance Ca2+-activated K+ channel; broadly expressed, including neurons and some vascular smooth muscle/pericytes.<br>- **SLC26A2** ‚Äì Sulfate transporter; classic chondrocyte/mesenchymal gene; in brain, points to mesenchymal/fibroblast-like identity.<br>- **SLC6A20** ‚Äì Proline/imidazole transporter; expressed in epithelial and some stromal cells.<br>- **SLC47A1 (MATE1)** ‚Äì Organic cation transporter; often in kidney/liver epithelia, but in brain can appear in barrier-associated or perivascular cells.<br>- **CUBN (Cubilin)** ‚Äì Endocytic receptor; canonical in kidney proximal tubule and some epithelia; in brain, when present, usually in **choroid plexus/epithelial-like or barrier-associated stromal** cells.<br>- **CHRNA6, CHRNB3** ‚Äì Nicotinic acetylcholine receptor subunits; typically dopaminergic neuron-associated (e.g., midbrain), but here they are low in the ranking and not accompanied by a strong neuronal program (no TH, SLC6A3, etc.), so likely incidental/low-level.<br><br>**D. Transcription factors / lineage regulators**<br><br>- **FOXP2** ‚Äì Transcription factor classically marking specific neuronal subtypes (e.g., corticothalamic projection neurons, striatal MSNs, some brainstem nuclei). However, FOXP2 can be lowly expressed in some non-neuronal cells in scRNA-seq; here it is at the bottom of the ranked list and not accompanied by a robust neuronal gene set, so it is unlikely to define the primary identity.<br>- **LMO3** ‚Äì LIM domain-only protein; neuronal TF, often in specific cortical interneurons/projection neurons. Again, present but not supported by a broader neuronal signature.<br><br>**E. Immune / complement / barrier-associated**<br><br>- **DNASE1L3** ‚Äì Secreted DNase; often in endothelial/immune-associated cells; can appear in perivascular fibroblast-like cells.<br>- **SPINT2** ‚Äì Kunitz-type serine protease inhibitor; barrier/epithelial and stromal expression.<br>- **HPR (Haptoglobin-related protein)** ‚Äì Plasma protein; can be expressed in liver and some barrier/vascular-associated cells.<br>- **C2orf40 (ECRG4)** ‚Äì Secreted peptide; tumor suppressor; enriched in choroid plexus and some ependymal/epithelial-like cells in brain.<br><br>**F. Other notable genes**<br><br>- **LAMP5** ‚Äì Lysosomal-associated membrane protein 5; canonical for L2 IT LAMP5 interneurons and some microglia-like populations. However, here it appears in a context dominated by ECM/fibroblast markers and without a strong neuronal synaptic program (no GAD1/2, SLC17A7, etc.), suggesting either low-level expression or contamination rather than defining identity.<br>- **INMT** ‚Äì Indolethylamine N-methyltransferase; metabolic enzyme; can be expressed in various stromal/epithelial cells.<br>- **EPHA7** ‚Äì Eph receptor; involved in axon guidance and also in vascular/stromal patterning.<br>- **PATJ** ‚Äì Tight junction-associated scaffold; barrier/epithelial and perivascular cells.<br>- **RCN3** ‚Äì ER-resident Ca2+-binding protein; enriched in secretory/ECM-producing cells, including fibroblasts and oligodendrocyte lineage.<br><br>2. Key cell-type‚Äìassociated markers<br>-----------------------------------<br><br>Now, grouping by canonical brain cell-type associations:<br><br>**A. Neuronal markers (weak/incomplete)**<br><br>- **LAMP5, CHRNA6, CHRNB3, FOXP2, LMO3, GPC5-AS1, CTXN3, PHACTR2** ‚Äì These are associated with specific neuronal subtypes (L2 IT LAMP5 interneurons, dopaminergic-associated nAChR subunits, corticothalamic FOXP2+ neurons, etc.).<br>- However:<br>  - No strong pan-neuronal markers (e.g., SNAP25, RBFOX3/NeuN, SYT1, SLC17A7, GAD1/2).<br>  - The top of the ranked list is dominated by ECM and fibroblast-like genes, not neuronal.<br>  - Thus, the neuronal markers are likely low-level/background or reflect a small contaminating fraction, not the main identity.<br><br>**B. Astrocyte markers (partial, but not dominant)**<br><br>- **APOE, CLU, IGFBP2, IGFBP5, CPE** ‚Äì All can be expressed in astrocytes.<br>- Missing: strong canonical astrocyte markers such as **GFAP, AQP4, SLC1A2, SLC1A3, ALDH1L1**.<br>- The ECM profile (DCN, OGN, ELN, SFRP2, FRZB, CTGF) is much more fibroblast-like than astrocytic.<br><br>**C. Oligodendrocyte / OPC markers (weak)**<br><br>- **ENPP6, RCN3** ‚Äì Seen in oligodendrocyte lineage, but:<br>  - No PLP1, MBP, MOG, PDGFRA, SOX10, OLIG1/2.<br>  - Again, likely shared ECM/secretory genes rather than defining oligodendroglia.<br><br>**D. Microglia / macrophage markers (weak)**<br><br>- **FGL2, RARRES2, DNASE1L3** ‚Äì Immune-modulatory/secreted factors.<br>- Missing: P2RY12, CX3CR1, TMEM119, AIF1, CSF1R, etc.<br>- So not a microglial cluster.<br><br>**E. Endothelial / pericyte / vascular smooth muscle / perivascular fibroblast markers**<br><br>- Strong ECM and vascular-associated genes: **DCN, OGN, ELN, FBLN1, NPNT, THSD4, EGFL6, SMOC2, CTGF, CEMIP, SFRP2, FRZB, ENPP6, NOV, RCN3**.<br>- Barrier/epithelial/vascular-associated: **CUBN, PATJ, SPINT2, HPR, C2orf40**.<br>- Secreted niche factors: **IGFBP2, IGFBP5, CLU, APOE, FGL2, RARRES2, ADIRF**.<br>- This constellation is highly characteristic of **perivascular fibroblast-like cells (also called vascular leptomeningeal cells, VLMCs, or meningeal/perivascular stromal cells)** in brain scRNA-seq atlases.<br><br>3. Cross-referencing with known scRNA-seq atlases and literature<br>----------------------------------------------------------------<br><br>Comparing this signature to published human and mouse brain atlases:<br><br>- **VLMC / perivascular fibroblast markers** (from Tasic et al., Zeisel et al., Saunders et al., and human datasets like Hodge et al., Lake et al., and more recent human cortex atlases):<br>  - Common markers: **SFRP2, FRZB, DCN, OGN, COL1A1/2, LUM, PDGFRA (sometimes), SMOC2, EGFL6, NPNT, FBLN1, THSD4, CEMIP, CTGF**.<br>  - Many of these are present here: **SFRP2, FRZB, DCN, OGN, SMOC2, EGFL6, NPNT, FBLN1, THSD4, CEMIP, CTGF**.<br>  - VLMCs often show **APOE, CLU, IGFBP2/5** and other secreted factors, consistent with this list.<br>- **Perivascular fibroblasts in human cortex** (e.g., Vanlandewijck et al., Nature 2018; Xie et al., Cell 2021):<br>  - Express **DCN, OGN, COL1A1/2, LUM, PDGFRA, SFRP2, FRZB, SMOC2, EGFL6, NPNT, THSD4**, and other ECM genes.<br>  - Often annotated as ‚ÄúVLMC‚Äù or ‚Äúperivascular fibroblast‚Äù in scRNA-seq.<br>- **Choroid plexus / ependymal / barrier-like cells**:<br>  - Express **CUBN, C2orf40 (ECRG4), CLU, APOE**, but typically also **TTR, KRT8/18, FOXJ1**, which are not in this list.<br>  - Here, the ECM/fibroblast signature is stronger than a pure epithelial/CP signature.<br><br>Thus, the profile matches **VLMC/perivascular fibroblast-like cells** much more closely than any neuronal or classic glial type.<br><br>4. Most probable general cell type<br>----------------------------------<br><br>Given:<br><br>- Strong, high-ranking ECM and Wnt-modulating genes (SFRP2, FRZB, DCN, OGN, CTGF, SMOC2, EGFL6, NPNT, FBLN1, THSD4, CEMIP, ELN).<br>- Secreted niche factors and apolipoproteins (APOE, CLU, IGFBP2/5, FGL2, RARRES2).<br>- Barrier/vascular-associated genes (CUBN, PATJ, SPINT2, C2orf40, HPR).<br>- Absence of robust neuronal, astrocytic, oligodendroglial, or microglial core markers.<br><br>The **most probable general cell type** is:<br><br>> **Perivascular fibroblast-like / vascular leptomeningeal cell (VLMC) / meningeal/perivascular stromal cell**<br><br>These are non-neuronal, non-glial stromal cells associated with blood vessels and meninges in brain.<br><br>5. Top 3 most probable sub-cell types (ranked)<br>----------------------------------------------<br><br>Within this general category, brain atlases often distinguish related subtypes:<br><br>1. **Perivascular fibroblast / VLMC (most likely)**  <br>   - Defining features in this list:<br>     - Strong fibroblast ECM program: **SFRP2, FRZB, DCN, OGN, CTGF, SMOC2, EGFL6, NPNT, FBLN1, THSD4, CEMIP, ELN**.<br>     - Wnt-modulating and CCN family genes: **SFRP2, FRZB, CTGF, NOV, NKD1**.<br>     - Secreted niche factors: **APOE, CLU, IGFBP2, IGFBP5, FGL2, RARRES2, ADIRF**.<br>   - This matches canonical VLMC/perivascular fibroblast clusters in both mouse and human cortex.<br><br>2. **Meningeal fibroblast / leptomeningeal stromal cell (second)**  <br>   - Meningeal fibroblasts share many markers with perivascular fibroblasts (DCN, OGN, SFRP2, FRZB, SMOC2, EGFL6, NPNT).<br>   - The presence of **C2orf40, CUBN, PATJ, SPINT2** suggests some barrier/lining function, which could be compatible with leptomeningeal stromal cells at the brain surface.<br>   - Without explicit meningeal-specific markers (e.g., CRABP1, PDGFRB/PDGFRA patterns, COL1A1/2, LUM in the list), I rank this second.<br><br>3. **Choroid plexus‚Äìassociated stromal/epithelial-like cell (third)**  <br>   - Supporting genes: **CUBN, C2orf40, CLU, APOE, IGFBP2**, which are seen in choroid plexus and CSF‚Äìbrain barrier contexts.<br>   - However, the signature is much more fibroblast/ECM-heavy than typical CP epithelial cells (which would show **TTR, KRT8/18, FOXJ1, AQP1**), so this is less likely than a perivascular/meningeal fibroblast.<br><br>**Most likely subtype:**  <br>> **Perivascular fibroblast / vascular leptomeningeal cell (VLMC)-like stromal cell**<br><br>6. Concise summary<br>-------------------<br><br>- The marker list is dominated by **ECM and Wnt-modulating genes** (SFRP2, FRZB, DCN, OGN, CTGF, SMOC2, EGFL6, NPNT, FBLN1, THSD4, CEMIP, ELN) and **secreted niche factors** (APOE, CLU, IGFBP2/5, FGL2, RARRES2, ADIRF), with **barrier/vascular-associated genes** (CUBN, PATJ, SPINT2, C2orf40).<br>- Canonical neuronal, astrocytic, oligodendroglial, and microglial core markers are largely absent, and the few neuronal-associated genes (LAMP5, CHRNA6, CHRNB3, FOXP2, LMO3) are low-ranking and not supported by a broader neuronal program.<br>- Cross-referencing with human and mouse brain scRNA-seq atlases, this profile matches **perivascular fibroblast / VLMC / meningeal stromal cells**.<br>- Final annotation: **Perivascular fibroblast-like (VLMC) stromal cells associated with brain vasculature/meninges**.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Perivascular fibroblast-like / vascular leptomeningeal cell (VLMC) stromal cell</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Perivascular fibroblast / VLMC</li><li>Meningeal fibroblast / leptomeningeal stromal cell</li><li>Choroid plexus‚Äìassociated stromal/epithelial-like cell</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Neuronal subtypes (LAMP5+, FOXP2+, CHRNA6+/CHRNB3+), likely low-level/contaminating</li><li>Astrocyte-like cells (APOE+, CLU+, IGFBP2/5+), partial overlap only</li><li>Oligodendrocyte lineage / OPC-like cells (ENPP6+, RCN3+), weak</li><li>Microglia/immune-interacting stromal cells (FGL2+, RARRES2+, DNASE1L3+), weak</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    